Lakefront Biotherapeutics N.V. (LKFT) Earnings History
Profitable22 years of earnings data (2004–2025) · Positive TTM net income
Loading earnings history...
Lakefront Biotherapeutics N.V. (LKFT) Earnings Overview
As of November 18, 2026, Lakefront Biotherapeutics N.V. (LKFT) reported trailing twelve-month net income of $796M, reflecting +334.8% year-over-year growth. The company earned $12.13 per diluted share over the past four quarters, with a net profit margin of 28.8%.
Looking at the long-term picture, LKFT's historical earnings data spans multiple years. The company achieved its highest annual net income of $321M in fiscal 2025, representing a new all-time high.
Lakefront Biotherapeutics N.V. maintains industry-leading profitability with a gross margin of 97.3%, operating margin of 45.1%, and net margin of 28.8%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including ARCT (-$78M net income, -97.9% margin), ACAD ($362M net income, 36.5% margin), HALO ($485M net income, 22.7% margin), LKFT has outperformed on profitability metrics. Compare LKFT vs ARCT →
LKFT Earnings vs Peers
Earnings metrics vs comparable public companies
LKFT Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $321M | +333.1% | $501M | $4.87 | 28.9% | 45.1% |
| 2024 | $74M | -65.0% | -$188M | $1.12 | 26.9% | -68.3% |
| 2023 | $212M | +197.1% | -$88M | $3.21 | 88.3% | -36.8% |
| 2022 | -$218M | -73.8% | -$131M | $-3.32 | -90.4% | -54.3% |
| 2021 | -$125M | +58.9% | -$166M | $-1.91 | -25.9% | -34.2% |
| 2020 | -$305M | -303.8% | -$179M | $-4.78 | -63.9% | -37.4% |
| 2019 | $150M | +612.1% | $369M | $2.60 | 17.9% | 44.2% |
| 2018 | -$29M | +74.7% | -$45M | $-0.56 | -10.1% | -15.5% |
| 2017 | -$116M | -314.2% | -$90M | $-2.34 | -91.0% | -70.7% |
| 2016 | $54M | +145.6% | -$11M | $1.14 | 41.7% | -8.9% |
| 2015 | -$118M | -456.5% | -$89M | $-3.32 | -299.3% | -226.1% |
| 2014 | $33M | +511.1% | -$37M | $1.10 | 47.9% | -52.8% |
| 2013 | -$8M | -41.2% | -$11M | $-0.28 | -5.9% | -8.0% |
| 2012 | -$6M | +82.7% | -$7M | $-0.22 | -4.2% | -4.9% |
| 2011 | -$33M | -857.4% | -$33M | $-1.25 | -34.5% | -34.3% |
| 2010 | $4M | +45.2% | $1M | $0.17 | 3.6% | 0.8% |
| 2009 | $3M | +120.6% | $2M | $0.13 | 3.2% | 1.8% |
| 2008 | -$15M | +33.6% | -$15M | $-0.69 | -18.9% | -19.8% |
| 2007 | -$22M | -93.6% | -$22M | $-1.06 | -33.3% | -33.1% |
| 2006 | -$11M | -73.3% | -$12M | $-0.84 | -32.2% | -33.6% |
| 2005 | -$7M | -82.3% | -$7M | $-0.73 | -58.2% | -59.2% |
| 2004 | -$4M | - | -$4M | $-0.60 | -46.1% | -46.4% |
Download Data
Export LKFT earnings history in CSV or JSON format
Free sign-in required to download data
LKFT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LKFT — Frequently Asked Questions
Quick answers to the most common questions about buying LKFT stock.
What is LKFT earnings per share (EPS)?
LKFT trailing twelve-month (TTM) diluted EPS is $12.13, reflecting +334.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2004 to 2025 is available in the table on this page.
What is Lakefront Biotherapeutics N.V.'s net income?
Lakefront Biotherapeutics N.V. (LKFT) trailing twelve-month net income is $796M as of 2025. Earnings grew +334.8% year-over-year. Lakefront Biotherapeutics N.V. has been profitable for 3 consecutive years.
Is LKFT profitable?
Yes, LKFT is profitable with a TTM net income of $796M and a net profit margin of +28.8%. Lakefront Biotherapeutics N.V. has generated profits for 3 consecutive years.
What is LKFT's earnings growth rate?
LKFT compound annual EPS growth rates (CAGR): 1-Year: +334.8%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2004 to 2025.
What are LKFT's profit margins?
Lakefront Biotherapeutics N.V. net profit margin is +28.8%, operating margin is +45.1%, and gross margin is +97.3%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +9.9%.
Is LKFT growing earnings?
Yes, LKFT earnings are accelerating — EPS growth of +334.8% exceeds the 5-year CAGR of N/A. TTM net income reached $796M. Earnings momentum is strengthening.
What was LKFT's best earnings year?
Lakefront Biotherapeutics N.V.'s highest annual net income on record is $321M, achieved in fiscal year 2025. Earnings history on this page spans 2004 to 2025 and includes all annual and quarterly figures.
What were LKFT's earnings last quarter?
LKFT's most recent reported quarter was Q3 2026. Net income was $-3M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.